Caesarea Medical Electronics

About Caesarea Medical Electronics

Established in 1993 by Swi and Anat Barak, Caesarea Medical Electronics (CME) is an Israeli manufacturer specializing in infusion and syringe pump systems. The company operates in the medical devices and supplies industry, catering to both hospital and homecare settings. Its business model revolves around the design, production, and sale of these devices, complemented by a range of disposable administration sets and accessories. CME also provides project-level customizations, such as specialized disposables and software language adaptations, to meet specific client needs.

The company's product portfolio is centered on smart infusion and syringe pumps designed for safety and ease of use. These devices are engineered to be compact and portable, making them suitable for specialized applications like IV and epidural anesthesia, pain management, and nutritional support in both clinical and home environments. The product line includes ambulatory pumps, multi-channel pumps like the BodyGuard 121 Twins™, and the T34 syringe pump.

CME demonstrated a significant growth trajectory, reporting annual revenues of $50-60 million and profits around $20 million in the years leading up to 2017. The company's journey includes a major investment in 2013 when CareFusion acquired a 40% stake for $100 million. This partnership evolved, and in April 2017, Becton, Dickinson and Company (BD), which had previously acquired CareFusion, purchased the remaining 60% of CME, valuing the company at approximately $250 million. This acquisition integrated CME's ambulatory and home care technologies into BD's broader infusion portfolio. As of early 2025, BD announced plans to close the Caesarea manufacturing plant by June 2025, transitioning production to other global facilities to streamline operations.